CareDx Transplant Patient App, AlloCare, Expands Access to the Majority of Transplant Patients
CareDx has launched the AlloCare app on the Android Play Store, complementing its availability on iOS, aimed at assisting organ transplant patients in managing their health pre-and-post-transplant. This user-friendly app offers features such as medication management, lab appointment scheduling, and biometric tracking, effectively doubling the total addressable user base. The app's design was heavily influenced by input from transplant recipients and patient organizations, ensuring it meets the specific needs of users, whether they are awaiting a transplant or years post-operation.
- AlloCare app now available on Android, doubling the user base.
- App features include managing medications, scheduling lab appointments, and viewing test results.
- Designed with input from transplant patients, enhancing user relevance and satisfaction.
- None.
AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that AlloCare, the app developed by CareDx for patients looking to manage their health before and after a transplant, has now launched on Android.
AlloCare is an easy-to-use mobile app designed to help organ transplant patients manage their health throughout the pre to post transplant journey with their mobile device. AlloCare allows patients to manage medications, schedule lab appointments, and view test results. Additionally, the app monitors biometrics and provides a platform for community engagement. With the launch on Android, the total addressable user base doubles.
“When we created this app, we wanted to make sure it would serve transplant recipients well, so we involved them in the design, testing, and implementation process,” said Sasha King, Chief Marketing Officer, CareDx. “Thanks to the help, insights and experience from patient organizations, including Transplant Recipients International Organization (TRIO), we have put together a truly patient-focused app that is specific to the needs before and after transplantation.”
“TRIO members have been involved with the design and testing of the AlloCare app for almost a year. By listening to real transplant patients, they’ve been able to build a comprehensive app that is customizable to various needs of patients whether they are still on the transplant waitlist or 20 years post-transplant,” said Jim Gleason, TRIO president and a heart transplant recipient.
Users can download the app in the iOS or Android app stores now. To learn more about AlloCare, visit www.caredx.com/allocare.
About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
CONTACTS:
CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com
Investor Relations
Greg Chodaczek
347-920-7010
investor@caredx.com
FAQ
What is the AlloCare app by CareDx?
When did CareDx launch the AlloCare app on Android?
What features does the AlloCare app offer?
How does the AlloCare app benefit transplant patients?
What is the stock symbol for CareDx?
